Rosuvastatin in the Long-term Treatment of Hypercholesterolaemic Subjects With Coronary Heart Disease
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate that 76 weeks of treatment with
rosuvastatin calcium 2.5-20 mg results in no progression of coronary artery atherosclerotic
volume as measured by intravascular ultrasonography (IVUS) imaging in hypercholesterolaemic
subjects with coronary heart disease (CHD).